Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aspen Aerogels Inc (ASPN) vs Crispr Therapeutics AG (CRSP) Price & Performance

Aspen Aerogels IncTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Aspen Aerogels Inc vs Crispr Therapeutics AG — how do they compare? Aspen Aerogels Inc trades at $6.09 (market cap $509.55M), while Crispr Therapeutics AG trades at $53.83 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 10.3× Aspen Aerogels Inc's market cap, and Aspen Aerogels Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.

ASPNCRSP
Market Cap
$509.55M$5.23B
Sector
TechnologyHealth
52-Week High
$8.82$76.78
52-Week Low
$2.57$44.34
Enterprise Value
$482.96M$3.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aspen Aerogels Inc

Aspen Aerogels (ASPN) trades at $6.13, down 2.54% today, with a bullish technical signal from moving averages despite mixed oscillators. The company shows improving revenue trends with Q2 2026 results beating expectations and strong Q3 guidance of $65-80 million revenue. However, profitability remains challenged with negative net income margins of -62.45% and consecutive quarterly EPS misses. Analyst sentiment is overwhelmingly positive with 82.61% buy ratings.

The outlook balances strong revenue growth potential in thermal barrier markets against persistent profitability challenges. Investment opportunity lies in the expanding EV thermal barrier business and European market growth, while risks include sustained negative cash flow and competitive pressures in evolving battery technologies.

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.

Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aspen Aerogels Inc

Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.

Read more on ASPN

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP